2024
Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story
Goldsweig A, Deng Y, Yao X, Desai N, Cohen D, Aronow H, Messé S, Ross J, Lansky A, Savitz S. Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010200. PMID: 38189127, PMCID: PMC10844981, DOI: 10.1161/circoutcomes.123.010200.Peer-Reviewed Original ResearchStroke/systemic embolismTransient ischemia attackPFO closureSystemic embolismIschemia attackRetrospective cohort studyTransient ischemic attackHalf of patientsOptumLabs Data WarehouseCommercial insurance enrolleesRegulatory approvalClinical trial publicationsIschemic attackRecurrent strokeCohort studyPatent foramenUnderwent closureAtrial fibrillationClinical trialsInsurance enrolleesDecompression illnessTrial publicationsOff labelPatientsProcedure volume
2017
Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Serrao GW, Lansky AJ, Mehran R, Stone GW. Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2017, 121: 678-683. PMID: 29394998, DOI: 10.1016/j.amjcard.2017.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsBiomarkersCoronary AngiographyFemaleHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsRecombinant ProteinsRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionStentsStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionLeft ventricular ejection fractionPrimary PCIAcute Myocardial Infarction trialMyocardial Infarction trialElevation myocardial infarctionHarmonizing OutcomesLVEF improvementMyocardial infarctionLower baseline left ventricular ejection fractionLeft ventricular ejection fraction improvementBaseline left ventricular ejection fractionGlycoprotein IIb/IIIa inhibitorsVentricular ejection fraction improvementMyocardial Infarction 3 flowIIb/IIIa inhibitorsEjection fraction improvementHalf of patientsPercutaneous coronary interventionVentricular ejection fractionPredictors of improvementPrespecified substudyPrimary stentingAngiographic predictors